Skip to main content
Novonesis AS logo

Novonesis AS — Investor Relations & Filings

Ticker · NSIS ISIN · DK0060336014 LEI · 529900T6WNZXD2R3JW38 CO Manufacturing
Open in API
Filings indexed 2,308 across all filing types
Latest filing 2022-02-01 Annual Report (ESEF)
Country DK Denmark
Listing CO NSIS

About Novonesis AS

https://www.novozymes.com/en

Novonesis is a global biosolutions company formed through the combination of Novozymes and Chr. Hansen. The company develops and produces a broad portfolio of biological solutions, including industrial enzymes, functional proteins, and microorganisms such as cultures, probiotics, and yeast. Its products are utilized in over 30 industries to improve efficiency, sustainability, and product quality. Key markets include food and beverage, where solutions enhance nutrition and reduce waste; human and animal health; agriculture, promoting higher crop yields and animal welfare; and household care, for more effective cleaning. Novonesis applies biotechnological principles to address global challenges in production and consumption, aiming to create more sustainable systems and products.

Recent filings

Filing Released Lang Actions
Annual Report (ESEF) 2021
Annual Report (ESEF) Classification · 100% confidence FY 2021
2022-02-01 English
Report Publication Announcement 2022
Report Publication Announcement Classification · 98% confidence The document text is extremely short (627 characters) and explicitly states 'Please read the attached' while providing links to downloadable files titled 'Group financial statement and annual report for 2021' and 'The-Novozymes-Report-2021'. This structure perfectly matches the 'MENU VS MEAL' rule, indicating that this document is an announcement about the availability of a report, not the report itself. Since it announces the publication of the annual report, the most appropriate classification is Report Publication Announcement (RPA). Although the content relates to an Annual Report (10-K), the format dictates RPA.
2022-02-01 English
Group financial statement and annual report for 2021
Annual Report Classification · 95% confidence The document is titled 'The Novozymes Report 2021' and contains extensive content including a message from the Chair and CEO, business strategy, performance highlights, detailed segment performance, corporate governance, risk management, remuneration report summary, and consolidated financial statements. The length is about 15,000 characters, indicating a comprehensive report rather than a brief announcement. The content covers full-year performance for 2021, including financial data and business analysis, which aligns with an official yearly report covering company activity and full financial performance. There is no indication that this is merely an announcement or a presentation, nor is it a transcript or a regulatory filing. Therefore, this document fits the definition of an Annual Report (10-K). FY 2021
2022-02-01 Danish
Group financial statement and annual report for 2021
Annual Report Classification · 95% confidence The document provides a detailed financial and operational performance overview for the full year 2021, including quarterly data (Q4 2021) and outlook for 2022. It includes comprehensive financial metrics such as organic sales growth, EBIT margin, ROIC, free cash flow, and segment sales breakdowns by business area and geography. The presence of detailed financial statements, performance analysis, and management commentary indicates this is a full annual financial report. There is no indication that this is merely an announcement or a summary; the length (15,000 characters) and depth of financial data confirm it is the actual report. Therefore, the document fits the definition of an Annual Report (10-K equivalent). FY 2021
2022-02-01 Danish
M&A Activity 2021
M&A Activity Classification · 99% confidence The document is a formal announcement dated November 30, 2021, titled 'Novozymes strengthens and expands position in human health and functional foods by acquiring a majority stake in Synergia Life Sciences'. It details a specific corporate action: the acquisition of a majority stake in another company, including financial terms (DKK ~1 billion), expected closing dates, and the impact on financial metrics (EBIT, ROIC, EPS). This content directly relates to corporate financing activities, capital structure changes, and major transactions. This aligns perfectly with the definition of 'Capital/Financing Update' (CAP). It is not an Earnings Release (ER) as it focuses on M&A, nor is it a full Annual Report (10-K) or Interim Report (IR).
2021-12-01 English
Trading by management and close relations of management
Director's Dealing Classification · 100% confidence The document is a formal notification of share transactions by a person discharging managerial responsibilities (Claus Crone Fuglsang, CSO and EVP). It explicitly cites the Market Abuse Regulation (EU) No 596/2014 and details the exercise of share options and subsequent sale of shares by an insider. This fits the definition of a Director's Dealing (DIRS) report.
2021-11-11 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.